October 14, 2016
Sensorion reports €4.3M loss for first half of 2016
Net loss amounts to €4.3M at June 30, 2016, compared with a net loss of €1.5M at June 30, 2015.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 14, 2016
IntegraGen Reports Loss for First Half of 2016
The net result over the first six months of 2016 was a loss of €1,028K compared to a loss of €872K in H1 2015.
October 14, 2016
Allergan partners with SonarMD in developing new IBS-D patient engagement platform
Allergan has announced a collaboration with SonarMD on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes.
October 14, 2016
Aeterna Zentaris licenses its anti-cancer Zoptrex in Australia and New Zealand
Canadian biopharmaceutical company Aeterna Zentaris, Inc., has signed an additional licensing agreement with Specialised Therapeutics Asia (“STA”) for its anti-cancer compound, Zoptrex.
October 13, 2016
Horizon Pharma offers $300M senior notes and borrows money for buying Raptor Pharmaceuticals
Horizon Pharma, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intends to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million.
October 13, 2016
Theradiag: Revenue growth at end September 2016 +31%
THERADIAG a company specializing in in vitro diagnostics and theranostics, has reported its consolidated revenues for the 3rd quarter of 2016.
October 13, 2016
STENTYS sees revenue up 26%over the first 9 months
STENTYS a medical technology company today announced its revenue for the third quarter and first 9 months to September 30, 2016.
October 13, 2016
Allergan’s BELKYRA Receives Marketing Authorisation In Sweden
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).
October 13, 2016
SpineGuard Reports €1.7M Revenue for 3Q 2016, and 9 Months Growth of 15%
SpineGuard announced today that its third quarter revenue grew to €1.7 million, a 2% increase compared with 3Q 2015.
October 13, 2016
Adocia Announces Third Quarter 2016 Financial Results
Adocia a clinical stage biopharmaceutical company announced today third quarter revenue and net cash position ending September 30,2016.